Advancing a proprietary pipeline

We have developed a proprietary pipeline of therapeutic peptides designed to safely and effectively drug central melanocortin 3 and 4 receptors (MC3R/MC4R) to treat many metabolic disorders and help people live healthier lives. Our lead assets include an oral MC3R/MC4R dual agonist for the treatment of general obesity, and an MC3R/MC4R dual antagonist to prevent and treat cachexia in patients with advanced cancers.